Skip to search formSkip to main contentSkip to account menu

Stimuvax

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

L-BLP25

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Micro- and Nanoparticulate Cancer Vaccines: A Vision for the Future
In lieu of an abstract, here is the article's first paragraph: Formulation scientists are constantly challenged with unique… 
Review
2010
Review
2010
L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study.
e13153 Background: The innovative cancer vaccine L-BLP25 (Stimuvax; BLP25 liposome vaccine) targets the MUC1 tumor-associated… 
2010
2010
Merck KGaA has temporarily suspended its clinical development program for Stimuvax (cancer vaccine BLP25)
  • 2010
  • Corpus ID: 195172882
2009
2009
further support ongoing Phase III study of Stimuvax in NSCLC • Development of Stimuvax adds to Merck KGaA's leading oncology program and commitment to personalizing cancer care
Orlando, FL, USA / Darmstadt, Germany, May 30, 2009 – Extended follow-up safety data from a randomized Phase IIb study of… 
2007
2007
A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease
3075 Background: L-BLP25 is an innovative cancer vaccine that incorporates a synthetic MUC1 lipopeptide in a liposomal delivery… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)